Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) will host a webcast on November 15, 2021, at 8:30 AM ET to discuss its Q3 2021 financials and provide business updates. Registration is available here. The company focuses on developing plant-based, non-opioid medications for gastrointestinal issues, including its approved product Mytesi (crofelemer), which treats noninfectious diarrhea in adults with HIV/AIDS. For further details, visit jaguar.health.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the appointment of Annabella Amatulli as chief regulatory officer for its Italian subsidiary, Napo EU S.p.A. Amatulli is recognized for her expertise in global regulatory affairs, having previously worked at Dompé and Janssen Pharmaceuticals. She will focus on strategic planning for Napo EU's development programs, particularly for crofelemer, aimed at addressing unmet gastrointestinal medical needs in Europe. The company aims to expedite the drug’s marketing authorization for short bowel syndrome with intestinal failure.
Jaguar Health (NASDAQ:JAGX) has filed a New Animal Drug Application (NADA) to obtain conditional FDA approval for Canalevia™-CA1, an oral, plant-based drug for treating chemotherapy-induced diarrhea (CID) in dogs. The application has been deemed complete, and commercialization is expected by late December 2021. With approximately 6 million new cancer diagnoses in dogs annually, this product addresses a significant need, as there are currently no FDA-approved treatments for CID in dogs. Additionally, Jaguar plans to seek approval for exercise-induced diarrhea (EID) treatment in 2022.
Jaguar Health announced the completion of its merger with Dragon SPAC, officially forming Napo EU S.p.A.
The merger received necessary governmental approvals, as confirmed by CEO Lisa Conte. The new entity will focus on expanding the market for Mytesi (crofelemer) in Europe, a plant-based treatment for noninfectious diarrhea, especially among patients with HIV/AIDS.
This merger aims to bolster Jaguar's presence in the European market, enhancing access to its innovative gastrointestinal pharmaceuticals.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the grant of nonstatutory stock options and restricted stock units (RSUs) to two new employees, effective October 25, 2021. New Employee 1 received options for 2,666 shares and 1,333 RSUs, while New Employee 2 received options for 1,583 shares and 791 RSUs, all with an exercise price of $2.02 per share. The options vest over three years, and the RSUs vest equally over the same period. These grants were approved by the Board's Compensation Committee as an incentive for the new hires.
Jaguar Health announced that the merger between its Italian subsidiary, Napo EU S.p.A., and Dragon SPAC S.p.A. is set to be completed within a week. The merger has received clearance from the Italian government under the 'Golden Powers' process. The new entity will hold an exclusive license for the crofelemer pipeline in Europe, with significant up-front fees and royalties due to Jaguar. Napo EU will primarily focus on obtaining conditional marketing authorization for crofelemer, aimed at treating short bowel syndrome.
Jaguar Health (NASDAQ:JAGX) announced updates on its crofelemer drug candidates and the merger with Dragon SPAC and Napo EU. The required regulatory notification for the merger has been submitted to the Italian government. The HALT-D study results on crofelemer for diarrhea prevention in breast cancer patients will be presented at the San Antonio Breast Cancer Symposium in December 2021. Additionally, discussions with the FDA regarding NP-300 for acute diarrhea relief were positive, and Canalevia for treating dogs' chemotherapy-induced diarrhea is set to launch in December 2021.
Jaguar Health, Inc. (JAGX) announces that Founder and CEO Lisa Conte will receive an Impact Award from Pure Earth for her dedication to supporting Indigenous communities and sustainable medicine. The award ceremony is set for October 4, 2021, in New York City. Under Conte's leadership, Jaguar developed crofelemer, the first FDA-approved plant-based oral medicine from the Croton lechleri tree, with over 800,000 trees planted. Pure Earth, recognized for its global pollution reduction efforts, praises Conte as a visionary in pharmaceuticals.
Jaguar Health (NASDAQ:JAGX) announced an R&D Showcase webinar on September 29, 2021, focusing on cancer therapy-related diarrhea (CTD). Hosted by Ladenburg Thalmann, the webinar will feature insights from leading oncologists and Jaguar's CEO Lisa Conte. The event aims to highlight the importance of supportive care for cancer patients struggling with diarrhea due to therapy. It is open to investors and financial analysts. Jaguar's subsidiaries focus on plant-based gastrointestinal medicines.
Jaguar Health announced on September 21, 2021, that it received confirmation from the FDA's Center for Veterinary Medicine that the Target Animal Safety section of its application for the conditional approval of Canalevia for chemotherapy-induced diarrhea (CID) in dogs is complete. Canalevia, an oral plant-based drug, aims to help dogs undergoing chemotherapy, addressing a significant issue as approximately 40% of treated dogs experience diarrhea that may affect treatment. Launch is expected in December 2021.